Biologics and biosimilars CDMOs in Europe: 66 compared (2026)
66 of the 255 contract development and manufacturing organisations in A4BEE’s European census list biologics and biosimilars manufacturing among their capabilities. The largest, with revenue over €1bn, are Catalent, Fujifilm Diosynth, Gedeon Richter, Insud Pharma (Chemo), Lonza, mAbxience and 3 more. 16 sit between €250m and €1bn and 41 are smaller or niche.
By ownership: 25 family-owned, 7 private equity, 14 listed, 16 part of a pharma or industrial group and 4 state-owned. They are spread across 22 countries, led by Poland (8), the United Kingdom (8), Italy (7), Germany (5) and the Netherlands (5). 32 of the 66 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.
66 companies
Biologics and biosimilars CDMOs in Europe
| Company | Country | Ownership | Size | Revenue (as reported) | Modalities | Data |
|---|---|---|---|---|---|---|
| CatalentTaken private by Novo Holdings (US$16.5 bn, Dec 2024); global but with EU sites. | Somerset, NJ, United States | Part of a pharma or industrial groupNovo Holdings | Tier 1 | ~US$4.4 bn FY2024 (global) | Biologics and biosimilars, Cell and gene therapy, Oral solid dose, Sterile fill-finish | medium |
| Fujifilm Diosynth~US$8 bn global capex; Hillerød (DK) site runs 12 bioreactors. | Billingham, United Kingdom | Part of a pharma or industrial groupFujifilm | Tier 1 | ~US$2.0 bn (global) | Biologics and biosimilars, Monoclonal antibody, Viral vector and vaccine, Cell and gene therapy | medium |
| Gedeon RichterPrimarily own-product/biosimilar pharma, but runs a real biologics CDMO arm (mammalian DS + fill-finish) and microbial CDMO via Richter-Helm. Group figures mostly non-CDMO. | Budapest, Hungary | Listed | Tier 1 | ~€2.1 bn (2023, group) | Biologics and biosimilars, Monoclonal antibody, Microbial and protein, Sterile fill-finish, Small-molecule API | high |
| Insud Pharma (Chemo)Group-level entity. Chemo industrial division provides CMO/CDMO across most dosage forms incl. injectables. Parent of Liconsa and León Farma. | Madrid, Spain | Family-ownedGrupo Insud | Tier 1 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish, Biologics and biosimilars, Monoclonal antibody | high |
| LonzaIntegrated Biologics grew +32.2% CER in 2025; the sector's clear scale + digital leader. | Basel, Switzerland | Listed | Tier 1 | CHF 6.5 bn (2025) | Biologics and biosimilars, Monoclonal antibody, Antibody-drug conjugate (ADC), Small-molecule API, Cell and gene therapy, Microbial and protein | high |
| mAbxienceBiosimilar developer and biologics CDMO; fully single-use technology at León. CDMO services confirmed. | León, Spain | Part of a pharma or industrial groupFresenius Kabi | Tier 1 | not disclosed | Monoclonal antibody, Biologics and biosimilars, Microbial and protein | high |
| OlonOne of Europe's largest API CDMOs; absorbed Euticals. Chemical synthesis + microbial fermentation, HPAPI, ADC bioconjugation. | Rodano, Italy | Family-owned | Tier 1 | ~€546 m (2024, group) | Small-molecule API, Microbial and protein, Peptide, Antibody-drug conjugate (ADC), Biologics and biosimilars | high |
| Patheon ItaliaItaly CDMO sites of Thermo Fisher (Patheon). Sterile/lyo + high-potency + mRNA/LNP. | Ferentino, Italy | Part of a pharma or industrial groupThermo Fisher Scientific | Tier 1 | not disclosed | Sterile fill-finish, Biologics and biosimilars, mRNA and LNP, Small-molecule API | low |
| SandozBiosimilars leader; CDMO/CMO is a secondary activity to its own portfolio. | Basel, Switzerland | Listed | Tier 1 | n/d | Biologics and biosimilars, Monoclonal antibody | low |
| AbzenaIntegrated biologics / bioconjugate / ADC CDMO+CRO, UK-founded but increasingly US-centred — European-HQ status borderline. Fills the ADC/bioconjugation gap. | Cambridge, United Kingdom | Private equityWelsh, Carson, Anderson & Stowe | Tier 2 | not disclosed | Biologics and biosimilars, Monoclonal antibody, Antibody-drug conjugate (ADC) | low |
| AlvotechReykjavik-based vertically-integrated biosimilars company (Nasdaq: ALVO). Core is its own biosimilar mAbs; 'Alvotech Contract Services' offers third-party biologics CDMO work. | Reykjavik, Iceland | Listed | Tier 2 | not disclosed | Monoclonal antibody, Biologics and biosimilars, Sterile fill-finish | medium |
| BioibéricaWorld-leading producer of heparin API + other biological-origin APIs; offers contract/custom manufacturing. CDMO role secondary. | Palafolls, Spain | Part of a pharma or industrial groupSARIA Group | Tier 2 | not disclosed | Biologics and biosimilars | medium |
| BiovetaLargest Czech veterinary immunobiological/pharma maker; dedicated contract-manufacturing function (vaccines, antisera, sterile forms). Primarily veterinary. | Ivanovice na Hané, Czechia | State-ownedCzech state (majority) | Tier 2 | not disclosed | Biologics and biosimilars, Viral vector and vaccine, Sterile fill-finish | medium |
| ChemiCustom/contract API manufacturing plus complex generics and proprietary peptides, low-molecular-weight heparins. | Cinisello Balsamo, Italy | Part of a pharma or industrial groupItalfarmaco Group | Tier 2 | not disclosed | Small-molecule API, Peptide, Biologics and biosimilars | high |
| Cobra Biologics (Charles River)Sweden-registered mammalian mAb/recombinant-protein site, now part of US Charles River. Standalone CDMO branding uncertain. | Södertälje, Sweden | Part of a pharma or industrial groupCharles River | Tier 2 | not disclosed | Monoclonal antibody, Biologics and biosimilars | medium |
| Delpharm | Boulogne, France | Family-owned | Tier 2 | ~€650 m | Oral solid dose, Sterile fill-finish, Biologics and biosimilars | medium |
| Fresenius Kabi Contract Manufacturing'Product Partnering' contract-manufacturing platform for sterile injectables, emulsions, liposomes and biologics. | Bad Homburg, Germany | ListedFresenius | Tier 2 | not disclosed | Sterile fill-finish, Biologics and biosimilars, Small-molecule API | medium |
| Haupt Pharma LatinaAenova Group's designated central sterile site. Third-party sterile fill-finish plus beta-lactam injectables and oral solids. | Latina, Italy | Part of a pharma or industrial groupAenova Group | Tier 2 | not disclosed | Sterile fill-finish, Oral solid dose, Monoclonal antibody, Peptide, Biologics and biosimilars | low |
| Just-Evotec BiologicsEvotec's biologics CDMO arm; J.POD Toulouse opened 2024 as its first EU facility. Distinct from the small-molecule Aptuit (Evotec) site. | Toulouse, France | ListedEvotec | Tier 2 | not disclosed | Monoclonal antibody, Biologics and biosimilars | medium |
| Merck KGaA CDMOLife-Science CDMO arm covering biologics, ADC/HPAPI, viral vectors and LNP (via Exelead). | Darmstadt, Germany | ListedE. Merck KG | Tier 2 | not disclosed | Monoclonal antibody, Biologics and biosimilars, Antibody-drug conjugate (ADC), Viral vector and vaccine, mRNA and LNP | medium |
| Morpho (Alfasigma CDMO)Alfasigma's dedicated third-party CDMO unit (rebranded 'Morpho' 2024). Sterile injectables, lyophilized products, vaccines, oral solids. | Bologna, Italy | Part of a pharma or industrial groupAlfasigma | Tier 2 | not disclosed | Sterile fill-finish, Oral solid dose, Biologics and biosimilars | high |
| NorthX BiologicsBiologics CDMO built on the former Cobra Biologics Matfors site; Swedish national innovation hub for ATMPs. | Matfors, Sweden | Private equityFlerie Invest | Tier 2 | not disclosed | Microbial and protein, Biologics and biosimilars, mRNA and LNP, Viral vector and vaccine, Cell and gene therapy, Monoclonal antibody, Sterile fill-finish | low |
| Novo Nordisk PharmatechThird-party supplier of quaternary ammonium APIs/excipients, recombinant insulin for media, and recombinant enzymes. Sells to external customers. | Køge, Denmark | Part of a pharma or industrial groupNovo Nordisk | Tier 2 | not disclosed | Small-molecule API, Microbial and protein, Biologics and biosimilars | high |
| Recipharm | Stockholm, Sweden | Private equityEQT | Tier 2 | €827 m (2024) | Sterile fill-finish, Oral solid dose, Biologics and biosimilars, mRNA and LNP, Viral vector and vaccine | high |
| Rentschler BiopharmaComplex-protein pure-play; exited CGT in 2025 to refocus on biologics. | Laupheim, Germany | Family-owned | Tier 2 | ~US$296 m (2025) | Biologics and biosimilars, Monoclonal antibody, Microbial and protein | medium |
| 53BiologicsSpanish biologics CDMO (2017); recombinant proteins from DNA to protein — cell line dev, banking, GMP manufacturing. | Boecillo, Spain | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, Microbial and protein | medium |
| APC / VLE TherapeuticsIrish-founded (UCD spinout). APC = process-dev/CMC; sister VLE runs the GMP 'factory of the future' — the group has genuine manufacturing. | Dublin, Ireland | Family-owned | Tier 3 | not disclosed | Small-molecule API, Biologics and biosimilars, Viral vector and vaccine, mRNA and LNP | high |
| Batavia BiosciencesBiologics CDMO: viral vaccines/vectors, oncolytic viruses, proteins/antibodies; proprietary yield platforms. Owned by CJ (2021). | Leiden, Netherlands | Part of a pharma or industrial groupCJ CheilJedang | Tier 3 | not disclosed | Biologics and biosimilars, Viral vector and vaccine, Monoclonal antibody | high |
| Bilthoven BiologicalsVaccine CDMO (inactivated polio, viral-vector/Vero platforms; also mAbs). Owned by Serum Institute of India. | Bilthoven, Netherlands | Family-ownedSerum Institute of India | Tier 3 | not disclosed | Viral vector and vaccine, Biologics and biosimilars, Monoclonal antibody | high |
| BioneerCombined CRO + CDMO; process dev and GMP/non-GMP manufacturing of recombinant proteins/enzymes. Not-for-profit GTS institute, DTU subsidiary. | Hørsholm, Denmark | State-ownedTechnical University of Denmark | Tier 3 | not disclosed | Biologics and biosimilars, Microbial and protein, Monoclonal antibody | high |
| BiotonAmong the world's top-eight commercial manufacturers of recombinant human insulin. | Warsaw, Poland | Listed | Tier 3 | n/d | Biologics and biosimilars, Sterile fill-finish | medium |
| Celon Pharma | Łomianki, Poland | Listed | Tier 3 | PLN 207 m (2024) | Small-molecule API, mRNA and LNP, Biologics and biosimilars | high |
| Celonic | Basel, Switzerland | Family-ownedJRS Group | Tier 3 | n/d | Monoclonal antibody, Biologics and biosimilars, Cell and gene therapy | medium |
| Cerbios-Pharma~50-year-old CDMO for HPAPIs, ADCs, recombinant proteins and live biotherapeutics; acquired by HAS Healthcare 2025. | Lugano, Switzerland | Private equityHAS Healthcare | Tier 3 | not disclosed | Small-molecule API, Antibody-drug conjugate (ADC), Biologics and biosimilars, Microbial and protein | high |
| CuridaFrom a 2015 buyout of Takeda's Elverum sterile-liquids plant. BFS + nasal-spray fill-finish CDMO, plus a small Bio-CDMO unit (mAbs for preclinical/diagnostic use). | Elverum, Norway | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Monoclonal antibody, Biologics and biosimilars | high |
| eXmoor PharmaIndependent full-service cell & gene therapy CDMO + CMC consultancy. | Bristol, United Kingdom | Private equityMVM Partners | Tier 3 | not disclosed | Cell and gene therapy, Viral vector and vaccine, Biologics and biosimilars | medium |
| GenIbet BiopharmaceuticalsBiologics CDMO: microbial, cell culture, viral process dev + cGMP manufacture plus fill-finish. Made mRNA material for Moderna. | Oeiras, Portugal | Part of a pharma or industrial groupRecipharm | Tier 3 | not disclosed | Biologics and biosimilars, Microbial and protein, Viral vector and vaccine, Cell and gene therapy, mRNA and LNP, Sterile fill-finish | high |
| GTP BiowaysBiologics CDMO (mAbs, proteins, nanodrugs, ADCs, fill-finish). Acquired by Italy's Olon; now Olon France. | Toulouse, France | Part of a pharma or industrial groupOlon Group | Tier 3 | ~€12 m | Monoclonal antibody, Biologics and biosimilars, Antibody-drug conjugate (ADC), Microbial and protein, Sterile fill-finish | high |
| HALIXMammalian biologics CDMO: viral vectors, vaccines, recombinant proteins (1,000L SUB). Made AstraZeneca's COVID vaccine. | Leiden, Netherlands | Family-ownedDroege Group | Tier 3 | not disclosed | Viral vector and vaccine, Biologics and biosimilars, Monoclonal antibody | high |
| HiTech HealthFirst Irish company licensed to contract-manufacture cell & gene therapies. End-to-end ATMP CDMO with EU/UK QP release. | Galway, Ireland | Family-owned | Tier 3 | not disclosed | Cell and gene therapy, Viral vector and vaccine, Biologics and biosimilars | high |
| IBI LorenziniAseptic manufacturing of sterile injectables (specialist in sterile penicillins/cephalosporins) plus oral, topical and biotech. | Aprilia, Italy | Family-ownedIbigen Group | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Biologics and biosimilars, Monoclonal antibody, Peptide | high |
| IcosagenEnd-to-end mammalian biologics CRDMO: antibody discovery/engineering, CHO cell-line/process dev, and a new GMP facility (50–1000L single-use) for Phase I/II drug substance. | Tartu, Estonia | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, Monoclonal antibody | high |
| InnoCore PharmaceuticalsDrug-delivery CDMO for long-acting injectables (microspheres, implants, depot gels) via proprietary SynBiosys polymers. | Groningen, Netherlands | Family-owned | Tier 3 | not disclosed | Peptide, Biologics and biosimilars, Sterile fill-finish | high |
| IntravaccVaccine CDMO for infectious-disease/therapeutic vaccines, PoC to Phase I/II. State-owned; sale announced. | Bilthoven, Netherlands | State-ownedDutch State | Tier 3 | not disclosed | Viral vector and vaccine, Biologics and biosimilars, Microbial and protein | high |
| Kaneka EurogentecBiologics CDMO: microbial proteins, GMP plasmid DNA, oligonucleotides, peptides; added GMP mRNA (made a COVID vaccine). | Seraing, Belgium | Part of a pharma or industrial groupKaneka | Tier 3 | not disclosed | Biologics and biosimilars, Microbial and protein, mRNA and LNP, Peptide | high |
| KeveltEU-GMP Estonian maker of sterile small-volume parenterals, sterile semi-solids and biological medicinal products; seeks contract-manufacturing partnerships. | Tallinn, Estonia | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Biologics and biosimilars | high |
| MabionPivoted from biosimilar developer to biologics CDMO; anchor Novavax COVID-antigen contract + Sartorius cooperation. | Konstantynów Łódzki, Poland | Listed | Tier 3 | n/d (Novavax-driven, volatile) | Biologics and biosimilars, Monoclonal antibody, Sterile fill-finish | low |
| NanoformNanoparticle drug-particle-engineering CDMO (CESS nanoforming for small molecules + a biologics platform); formulation, analytical + GMP API. Nasdaq First North. | Helsinki, Finland | Listed | Tier 3 | not disclosed | Small-molecule API, Biologics and biosimilars | high |
| NerPharMaHPAPI/oncology CDMO offering integrated drug substance + drug product: injectables and oral solids. EMA + FDA accredited. | Nerviano, Italy | Part of a pharma or industrial groupBenta Group (Lebanon) | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Biologics and biosimilars, Small-molecule API | high |
| Northway BiotechCEE cost-competitive biologics CDMO scaling to 5,000 L stainless steel. | Vilnius, Lithuania | Family-owned | Tier 3 | n/d | Monoclonal antibody, Microbial and protein, Biologics and biosimilars, Sterile fill-finish, Viral vector and vaccine, Cell and gene therapy | medium |
| Nova LaboratoriesIndependent aseptic-processing CDMO + 'Specials' supplier; sterile fill-finish for clinical-trial medicines. | Leicester, United Kingdom | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Monoclonal antibody, Biologics and biosimilars, Microbial and protein | medium |
| Oxford BiomedicaLSE-listed pure-play viral-vector / cell & gene therapy CDMO (lentiviral, AAV, adenoviral). | Oxford, United Kingdom | Listed | Tier 3 | £128.8 m (FY2024) | Viral vector and vaccine, Cell and gene therapy, Biologics and biosimilars, mRNA and LNP | high |
| Paras BiopharmaceuticalsFounder-led microbial-biologics CDMO: recombinant biologics/biosimilars in microbial systems, plus peptides and proteins. Scales 10L→750L+. | Oulu, Finland | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, Microbial and protein, Peptide | medium |
| Polfa TarchominState-owned; anti-infectives + insulin + ampoules/vials/lyo. | Warsaw, Poland | State-owned | Tier 3 | n/d | Small-molecule API, Biologics and biosimilars, Sterile fill-finish | medium |
| Polpharma BiologicsJune 2025 demerger: biosimilars brand stays as Polpharma Biologics (operating from Switzerland); the CDMO becomes Rezon Bio. | Gdańsk, Poland | Family-ownedPolpharma | Tier 3 | ~US$18–100 m est. | Biologics and biosimilars, Monoclonal antibody, Microbial and protein | low |
| Polymun ScientificFamily-owned biopharma/liposome-LNP CDMO; scaled the LNP process for the BioNTech/Pfizer Comirnaty vaccine. | Klosterneuburg, Austria | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, mRNA and LNP, Viral vector and vaccine | high |
| ProBioGenIndependent biologics CDMO (proteins/antibodies, viral vectors, vaccines); Charité spin-off, founded 1994. | Berlin, Germany | Family-owned | Tier 3 | not disclosed | Monoclonal antibody, Biologics and biosimilars, Viral vector and vaccine | medium |
| Pure BiologicsAntibody/aptamer discovery + protein production (CRO). | Wrocław, Poland | Listed | Tier 3 | ~US$15 m est. | Monoclonal antibody, Biologics and biosimilars | medium |
| Rezon BioCDMO carved out of Polpharma Biologics (June 2025); positions to be Europe's most cost-competitive CDMO. | Gdańsk, Poland | Family-ownedPolpharma | Tier 3 | n/d | Biologics and biosimilars, Monoclonal antibody, Microbial and protein | low |
| Richter BiologicsGerman microbial/biologics CDMO. | Hamburg, Germany | Family-owned | Tier 3 | n/d | Biologics and biosimilars, Microbial and protein | low |
| Symbiosis Pharmaceutical ServicesIndependent sterile aseptic fill-finish CDMO (clinical + commercial): mAbs, ATMPs, viral vectors, ADCs, vaccines. FDA-inspected. | Stirling, United Kingdom | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Monoclonal antibody, Antibody-drug conjugate (ADC), Biologics and biosimilars, Cell and gene therapy, Small-molecule API | medium |
| Synthaverse (Biomed-Lublin)BCG vaccines + immunoglobulins + probiotics. | Lublin, Poland | Listed | Tier 3 | ~US$14 m est. | Viral vector and vaccine, Biologics and biosimilars | medium |
| ten23 healthSterile drug-product formulation & fill-finish CDMO (biologics, cell & gene therapy); absorbed swissfillon (Visp) in 2021. | Basel, Switzerland | Private equity3i Group | Tier 3 | not disclosed | Sterile fill-finish, Biologics and biosimilars, Cell and gene therapy | high |
| Upperton Pharma SolutionsSpray-drying specialist CDMO: formulation + dosage-form dev for oral, nasal, pulmonary and sterile forms (small molecules + biologics). | Nottingham, United Kingdom | Private equityInflexion | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish, Biologics and biosimilars | high |
| Wellgem BiopharmaBiologics contract dev/manufacturing: mammalian + microbial cell-line/process dev, cGMP cell banking, Phase II pilot facility. Newer entrant. | Vilnius, Lithuania | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, Monoclonal antibody, Microbial and protein, Viral vector and vaccine, Cell and gene therapy | medium |
| Wockhardt UK (CP Pharmaceuticals)UK operating entity; third-party contract manufacture of sterile injectables (vials, cartridges, ampoules, lyo) alongside own generics. | Wrexham, United Kingdom | Part of a pharma or industrial groupWockhardt (India) | Tier 3 | not disclosed | Sterile fill-finish, Small-molecule API, Biologics and biosimilars | medium |
Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).
Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.
Browse the census
Other European CDMO lists
By country
- CDMOs in Italy (31)
- CDMOs in Spain (30)
- CDMOs in Germany (28)
- CDMOs in the United Kingdom (25)
- CDMOs in France (15)
- CDMOs in Switzerland (14)
- CDMOs in Poland (11)
- CDMOs in Belgium (9)
- CDMOs in Sweden (9)
- CDMOs in Greece (8)
- CDMOs in Ireland (8)
- CDMOs in the Netherlands (8)
- CDMOs in Portugal (8)
- CDMOs in Denmark (7)
- CDMOs in Austria (5)
- CDMOs in Finland (5)
- CDMOs in Norway (5)
- CDMOs in Czechia (4)
- CDMOs in Lithuania (4)
- CDMOs in Bulgaria (3)
By modality
- Small-molecule API CDMOs in Europe (107)
- Oral solid dose CDMOs in Europe (94)
- Sterile fill-finish CDMOs in Europe (106)
- Biologics and biosimilars CDMOs in Europe
- Monoclonal antibody CDMOs in Europe (36)
- Antibody-drug conjugate (ADC) CDMOs in Europe (15)
- Cell and gene therapy CDMOs in Europe (29)
- mRNA and LNP CDMOs in Europe (22)
- Viral vector and vaccine CDMOs in Europe (32)
- Microbial and protein CDMOs in Europe (34)
- Peptide CDMOs in Europe (24)